MyD88-IN-3

MyD88-IN-3 is an orally active, selective MyD88 Inhibitor. MyD88-IN-3 specifically targets the TIR domain of MyD88 (KD = 28.5 μM), thereby preventing MyD88 self-polymerization and interaction with TLRs, which suppresses the activation of MAPK and NF-κB pathways. MyD88-IN-3 demonstrates significant anti-inflammatory efficacy and effectively mitigates Acute Lung Injury (ALI) symptoms in CLP (cecal ligation and puncture) and Lipopolysaccharides (HY-D1056) (LPS) -induced ALI models. MyD88-IN-3 can be used for the study of ALI[1].

Product Specifications

UNSPSC

12352005

Target

JNK; MyD88; NF-κB; p38 MAPK; Toll-like Receptor (TLR)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Smiles

O=S(C1=CC=C(N2CCN(CC3=CC=C(C#N)C=C3)CC2)C([N+]([O-])=O)=C1)(NC4=CC=C(OC)N=C4)=O

Molecular Formula

C24H24N6O5S

Molecular Weight

508.55

References & Citations

[1]Chen P, et al. Discovery of MyD88-IN-3 as an Orally Bioavailable, TIR Domain Selective, and Potent MyD88 Inhibitor for the Treatment of Acute Lung Injury. J Med Chem. 2025 Sep 25;68 (18) :19626-19644.